ABSTRACT
Rhinitis is present in 74% 3% (range 66-80%) of chronic fatigue syndrome (CFS) subjects (1-3). These subjects will be an increasing component of the patient mix seen by the allergist and rhinologist. This is unavoidable, as switching of drugs to over-the-counter status and the introduction of generic medications will lead to more widespread access to satisfactory treatment of allergic rhinitis (AR). Rhinitis subjects who fail self-medication and primary health care treatment plans will have severe AR and the nonallergic rhinitis (NAR) syndromes that we have discussed in this book. A significant number of these ‘‘treatment failures’’ will have additional complaints that are commonly, but mistakenly, interpreted as being of ‘‘allergic’’ or ‘‘atopic’’ origin. Many of these subjects will have CFS, fibromyalgia (FM), or one of their spectra of overlapping, associated illnesses. These subjects and their nonallergic disorders are the future for our clinical practices.
